news
Promising new bioactive material to regenerate cartilage
A biomaterial that improved hyaline cartilage repair could be used to avoid knee replacements and treat injuries and degenerative diseases.
List view / Grid view
Therapeutics
article
Exploring the potential of ADCs beyond oncology
Antibody Drug Conjugates (ADCs) are already deployed as part of the roster of oncology treatments, but here, Mike Ward, Head of Thought Leadership for Life Sciences & Healthcare, Clarivate, looks into their potential to help treat a whole range of other diseases and conditions. He discusses the barriers and enablers…
article
Restoring TERT to attenuate ageing hallmarks
In this Q&A, Dr Ronald DePinho of MD Anderson elucidates their preclinical proof-of-concept that adjusting TERT levels could be a viable therapeutic approach for mitigating age-related diseases, such as cancer, heart disease and Alzheimer’s.
news
Spinal muscular atrophy: searching for a cure
Organoids with SMA-pathology uncovered key findings about the disease, which could be utilised to develop new therapeutic options.
podcasts
How mRNA technology could revolutionise therapeutics
In this episode, we explore how mRNA technology could revolutionise cancer therapeutics.
news
Mini-lungs enable breakthroughs in SARS-CoV-2 research
Researchers discovered two potential new drug applications with the possible clinical use of surfactant early in COVID-19 cases.
article
Supercharging conventional monoclonal antibodies
In this Q&A, Krishna Polu and Dennis Pedersen, senior leaders of Commit Biologics, which is backed by Novo Holdings and Bioqube Ventures, elucidate how their technology differs from other existing therapeutic platforms and highlight its implications for the treatment of both cancer and autoimmune disease.
news
New agreement to progress cardiovascular disease research
The agreement between Cartherics, The University of Sydney and The University of Queensland will further stem cell-derived heart muscle therapy for heart failure.
news
The role of KDR in the survival of HTLV-1-infected T cells
KDR inhibitors could be very impactful for treatment of ATLL and HAM/TSP or prevent disease by lessening the viral load of HTLV-1.
news
Predicting persistent taxane-induced peripheral neuropathy
Researchers have developed a prediction model to ascertain breast cancer survivors’ risk of persistent taxane-induced peripheral neuropathy.
news
Rare types of helper T cells uncovered
Researchers have created a new T cell atlas which could aid the development of novel drug therapies for immune-mediated diseases.
news
Elucidating the pathophysiology of migraines
Researchers show that proteins released from the brain during migraine with aura are transported by CSF to pain-signalling nerves.
article
Could illuminating the surfaceome help find new targeted cancer therapies?
At the heart of precision oncology is the need to increase our understanding and knowledge of surface proteins found on tumour cells. Here Roman Thomas, CEO of DISCO Pharmaceuticals, explains how it is using cutting-edge technology to explore the surfaceome – a map of the proteins on the cell’s surface…
news
Overcoming chemotherapy resistance in pancreatic cancer
Researchers have discovered that pancreatic cancer’s resistance to chemotherapy is related to the physical stiffness of the extracellular matrix.
article
Women in Stem with Morgane Rousselot
We had the privilege of speaking to Morgane Rousselot, co-founder and CEO of SeaBeLife for our Women in Stem series. With a strong scientific background and over two decades of entrepreneurial experience in the biotechnology field, she leads the company with a team-focused approach and intellectual rigor.
